Table 3 Subgroup analysis of patients requiring repeat plasma CMV viral load testing
From: Diagnostic stewardship to limit repeat plasma cytomegalovirus viral load testing
|  | CMV VL testing ordered in intervals < 5 days before the feedback [IRR (95% CI)] | CMV VL testing ordered in intervals < 5 days after the feedback [IRR, (95% CI)] | CMV DNAemia [RR, (95% CI)] | CMV VL > 1,000 IU/mL [RR, (95% CI)] | CMV disease [RR, (95% CI)] |
|---|---|---|---|---|---|
General ward | 0.57 (0.46–0.70)** | 0.48 (0.39–0.60)** | 0.96 (0.75–1.23) | 1.05 (0.78–1.42) | 1.04 (0.59–1.81) |
ICU | 0.43 (0.28–0.64)** | 0.22 (0.13–0.37)** | 0.83 (0.62–1.12) | 1.08 (0.72–1.62) | 1.16 (0.50–2.68) |
Kidney transplant | 0.36 (0.17–0.77)* | 0.27 (0.12–0.64)* | 1.17 (0.75–1.84) | 1.27 (0.71–2.27) | 1.86 (0.76–4.54) |
HSCT | 1.11 (0.79–1.58) | 1.11 (0.79–1.58) | 0.95 (0.44–2.01) | 0.98 (0.39–2.47) | 0.84 (0.56–12.63) |
Autoimmune disease | 0.22 (0.13–0.37)** | 0.05 (0.18–0.13)** | 0.87 (0.61–1.27) | 0.98 (0.62–1.54) | 1.50 (0.52–4.34) |
Leukaemia | 0.54 (0.26–1.09) | 0.39 (0.18–0.86)* | 0.60 (0.17–2.24) | 0.61 (0.12–3.12) | 0.03 (0.00–0.21)** |
Solid malignancy | 0.15 (0.37–0.65)* | 0.09 (0.01–0.66)* | 0.89 (0.42–1.88) | 1.33 (0.55–3.22) | 0.66 (0.84–5.30) |